Genomic classification and risk stratification of bladder cancer

Damiano Fantini, Joshua J. Meeks*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Bladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer treatment. Here, we review the genomic and transcriptomic features associated with risk stratification in bladder cancer and summarize the current efforts for precision oncology in localized urothelial carcinomas.

Original languageEnglish (US)
Pages (from-to)1751-1757
Number of pages7
JournalWorld journal of urology
Issue number9
StatePublished - Sep 1 2019


  • Biomarker
  • Bladder cancer
  • Classifier
  • Genetic mutation
  • Risk-classification

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Genomic classification and risk stratification of bladder cancer'. Together they form a unique fingerprint.

Cite this